Please use this identifier to cite or link to this item:
Title: Granulocyte macrophage colony-stimulating factor auto-antibodies and disease relapse in inflammatory bowel disease.
Authors: Däbritz, Jan;Bonkowski, Erin;Chalk, Claudia;Trapnell, Bruce C;Langhorst, Jost;Denson, Lee a;Foell, Dirk
Keywords: Adolescent;Adult;Aged;Autoantibodies;Autoantibodies: immunology;Biological Markers;Biological Markers: analysis;Child;Child, Preschool;Enzyme-Linked Immunosorbent Assay;Feces;Feces: chemistry;Female;Granulocyte-Macrophage Colony-Stimulating Factor;Granulo
Issue Date: 2013
Abstract: OBJECTIVES: Along with others, we have reported that neutralization of granulocyte macrophage colony-stimulating factor (GM-CSF) increases intestinal permeability and bacterial translocation, and reduces neutrophil bacterial killing and anti-microbial seroreactivity. The objective was to investigate the utility of serum GM-CSF auto-antibody (Ab) as a marker for confirmation of stable remission and prediction of relapses in patients with inflammatory bowel disease (IBD).\n\nMETHODS: We consecutively included 181 adults and children with Crohn's disease (CD, n=61) or ulcerative colitis (UC, n=120). Over a 3-year period, we collected 861 serum samples and 610 stool samples during regular follow-up visits. GM-CSF Abs and fecal S100 proteins were measured by an enzyme-linked immunoassay.\n\nRESULTS: Serum GM-CSF Ab levels correlated with disease activity, location, and extent. Time course analysis before and after relapse showed a clear increase of GM-CSF Ab concentrations up to 6 months before clinical relapse. At 1.7 μg/ml (CD) and 0.5 μg/ml (UC), the sensitivity and specificity of GM-CSF Ab for predicting relapse already 2-6 months earlier were 88% and 95% in CD and 62% and 68% in UC, respectively. A baseline GM-CSF Ab level of >1.7 μg/ml was significantly associated with relapse of CD within 18 months.\n\nCONCLUSIONS: As GM-CSF is required for myeloid cell antimicrobial functions and homeostatic responses to tissue injury, serum GM-CSF Ab levels might reflect the degree of bowel permeability and bacterial translocation. Therefore, GM-CSF Ab might identify IBD patients at risk of disease relapse at an early stage, which makes the test a potential tool for monitoring disease activity and optimizing therapy.
Appears in Collections:Gastroenterology

Files in This Item:
File Description SizeFormat 
2013 Gastroenterology (3).pdf202.97 kBAdobe PDFThumbnail

Items in HannanDL are protected by copyright, with all rights reserved, unless otherwise indicated.